PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary ...
PHC has partnered with CCRM to boost cell quality with advanced T-cell expansion solutions. Takeaway Points PHC has ...
T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...
GloboCare has received a Notice of Allowance from the China National Intellectual Property Administration for its patent ...
Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and laboratory services, announced today that it has received a Notice of Allowance ...
GlobalData on MSN9d
BMS’ Phase II trial of CAR T cell therapy meets primary endpointBristol Myers Squibb (BMS) has reported that the multi-centre Phase II TRANSCEND FL trial assessing its cluster of ...
The off-the-shelf chimeric antigen receptor T-cell therapy P-BCMA-ALLO1 was shown to be safe and elicited strong anti-tumor ...
The evolution of cell and gene therapy is reshaping drug discovery, providing new hope for rare diseases and cancer through innovative gene editing approaches.
Galapagos is dropping its junior CD19 CAR-T as part of the Belgian biotech’s seemingly never-ending mission to recalibrate ...
PHC Corporation has signed a Master Collaboration Agreement with CCRM to work together on the development of primary T-cell(*1) expansion culture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback